Renal protective effects of efonidipine in partially nephrectomized spontaneously hypertensive rats

Keiji Fujiwara, Yoshihiko Kanno, Koichi Hayashi, Tsuneo Takenaka, Takao Saruta

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

We investigated the effects of a calcium antagonist, efonidipine, which was reported to dilate not only afferent arterioles but also efferent arterioles, on progression of renal failure in salt-loaded partially nephrectomized spontaneously hypertensive rats (SHR). Forty-four SHR's with 5 of 6 nephrectomy were divided into four groups: group I as control (n=20); group 2, efonidipine-treated (n=8); group 3, enalapril-treated (n=8); and group 4, nifedipine-treated (n=8). The rats were given these drugs and a high-salt diet (5% NaCl) for 8 weeks. During the experiment, systolic blood pressure (SBP) and daily urinary, protein excretion were measured every 2 weeks. At the end of the study, serum creatinine was determined, and renal tissues were obtained for light microscopic examination. SBP was markedly reduced by 8-week antihypertensive treatment. (control, 267±7 mmHg; efonidipine, 181±7 mmHg; enalapril, 200±12 mmHg; nifedipine, 184±6 mmHg). Glomerular sclerosis developed markedly in the control group, but was partially prevented in all treated groups. Similarly, urinary protein excretion (UPE) was suppressed by efonidipine (180±16 mg/day) and enalapril (186±16 mg/day vs. 301±28 mg/day for control). In contrast, nifedipine failed to prevent the increase in urinary protein excretion (258±22 mg/day). In conclusion, efonidipine attenuates SBP increase and ameliorates glomerular injury as well as nifedipine and enalapril. Furthermore, beneficial effects of efonidipine, but not nifedipine, on proteinuria suggest that different mechanisms mediate the improvement of proteinuria; one possible mechanism could be efferent arteriolar dilation, not reported in nifedipine.

Original languageEnglish
Pages (from-to)295-312
Number of pages18
JournalClinical and Experimental Hypertension
Volume20
Issue number3
Publication statusPublished - 1998 Apr

Fingerprint

Inbred SHR Rats
Nifedipine
Enalapril
Blood Pressure
Kidney
Arterioles
Proteinuria
Salts
Proteins
Sclerosis
Nephrectomy
Antihypertensive Agents
Renal Insufficiency
efonidipine
Dilatation
Creatinine
Diet
Calcium
Light
Control Groups

Keywords

  • Calcium antagonists
  • Efonidipine
  • Enalapril
  • Glomerular injury
  • Hypertension
  • Nifedipine

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Fujiwara, K., Kanno, Y., Hayashi, K., Takenaka, T., & Saruta, T. (1998). Renal protective effects of efonidipine in partially nephrectomized spontaneously hypertensive rats. Clinical and Experimental Hypertension, 20(3), 295-312.

Renal protective effects of efonidipine in partially nephrectomized spontaneously hypertensive rats. / Fujiwara, Keiji; Kanno, Yoshihiko; Hayashi, Koichi; Takenaka, Tsuneo; Saruta, Takao.

In: Clinical and Experimental Hypertension, Vol. 20, No. 3, 04.1998, p. 295-312.

Research output: Contribution to journalArticle

Fujiwara, K, Kanno, Y, Hayashi, K, Takenaka, T & Saruta, T 1998, 'Renal protective effects of efonidipine in partially nephrectomized spontaneously hypertensive rats', Clinical and Experimental Hypertension, vol. 20, no. 3, pp. 295-312.
Fujiwara, Keiji ; Kanno, Yoshihiko ; Hayashi, Koichi ; Takenaka, Tsuneo ; Saruta, Takao. / Renal protective effects of efonidipine in partially nephrectomized spontaneously hypertensive rats. In: Clinical and Experimental Hypertension. 1998 ; Vol. 20, No. 3. pp. 295-312.
@article{4b5d60f646a4465ba3675368d9541215,
title = "Renal protective effects of efonidipine in partially nephrectomized spontaneously hypertensive rats",
abstract = "We investigated the effects of a calcium antagonist, efonidipine, which was reported to dilate not only afferent arterioles but also efferent arterioles, on progression of renal failure in salt-loaded partially nephrectomized spontaneously hypertensive rats (SHR). Forty-four SHR's with 5 of 6 nephrectomy were divided into four groups: group I as control (n=20); group 2, efonidipine-treated (n=8); group 3, enalapril-treated (n=8); and group 4, nifedipine-treated (n=8). The rats were given these drugs and a high-salt diet (5{\%} NaCl) for 8 weeks. During the experiment, systolic blood pressure (SBP) and daily urinary, protein excretion were measured every 2 weeks. At the end of the study, serum creatinine was determined, and renal tissues were obtained for light microscopic examination. SBP was markedly reduced by 8-week antihypertensive treatment. (control, 267±7 mmHg; efonidipine, 181±7 mmHg; enalapril, 200±12 mmHg; nifedipine, 184±6 mmHg). Glomerular sclerosis developed markedly in the control group, but was partially prevented in all treated groups. Similarly, urinary protein excretion (UPE) was suppressed by efonidipine (180±16 mg/day) and enalapril (186±16 mg/day vs. 301±28 mg/day for control). In contrast, nifedipine failed to prevent the increase in urinary protein excretion (258±22 mg/day). In conclusion, efonidipine attenuates SBP increase and ameliorates glomerular injury as well as nifedipine and enalapril. Furthermore, beneficial effects of efonidipine, but not nifedipine, on proteinuria suggest that different mechanisms mediate the improvement of proteinuria; one possible mechanism could be efferent arteriolar dilation, not reported in nifedipine.",
keywords = "Calcium antagonists, Efonidipine, Enalapril, Glomerular injury, Hypertension, Nifedipine",
author = "Keiji Fujiwara and Yoshihiko Kanno and Koichi Hayashi and Tsuneo Takenaka and Takao Saruta",
year = "1998",
month = "4",
language = "English",
volume = "20",
pages = "295--312",
journal = "Clinical and Experimental Hypertension",
issn = "1064-1963",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Renal protective effects of efonidipine in partially nephrectomized spontaneously hypertensive rats

AU - Fujiwara, Keiji

AU - Kanno, Yoshihiko

AU - Hayashi, Koichi

AU - Takenaka, Tsuneo

AU - Saruta, Takao

PY - 1998/4

Y1 - 1998/4

N2 - We investigated the effects of a calcium antagonist, efonidipine, which was reported to dilate not only afferent arterioles but also efferent arterioles, on progression of renal failure in salt-loaded partially nephrectomized spontaneously hypertensive rats (SHR). Forty-four SHR's with 5 of 6 nephrectomy were divided into four groups: group I as control (n=20); group 2, efonidipine-treated (n=8); group 3, enalapril-treated (n=8); and group 4, nifedipine-treated (n=8). The rats were given these drugs and a high-salt diet (5% NaCl) for 8 weeks. During the experiment, systolic blood pressure (SBP) and daily urinary, protein excretion were measured every 2 weeks. At the end of the study, serum creatinine was determined, and renal tissues were obtained for light microscopic examination. SBP was markedly reduced by 8-week antihypertensive treatment. (control, 267±7 mmHg; efonidipine, 181±7 mmHg; enalapril, 200±12 mmHg; nifedipine, 184±6 mmHg). Glomerular sclerosis developed markedly in the control group, but was partially prevented in all treated groups. Similarly, urinary protein excretion (UPE) was suppressed by efonidipine (180±16 mg/day) and enalapril (186±16 mg/day vs. 301±28 mg/day for control). In contrast, nifedipine failed to prevent the increase in urinary protein excretion (258±22 mg/day). In conclusion, efonidipine attenuates SBP increase and ameliorates glomerular injury as well as nifedipine and enalapril. Furthermore, beneficial effects of efonidipine, but not nifedipine, on proteinuria suggest that different mechanisms mediate the improvement of proteinuria; one possible mechanism could be efferent arteriolar dilation, not reported in nifedipine.

AB - We investigated the effects of a calcium antagonist, efonidipine, which was reported to dilate not only afferent arterioles but also efferent arterioles, on progression of renal failure in salt-loaded partially nephrectomized spontaneously hypertensive rats (SHR). Forty-four SHR's with 5 of 6 nephrectomy were divided into four groups: group I as control (n=20); group 2, efonidipine-treated (n=8); group 3, enalapril-treated (n=8); and group 4, nifedipine-treated (n=8). The rats were given these drugs and a high-salt diet (5% NaCl) for 8 weeks. During the experiment, systolic blood pressure (SBP) and daily urinary, protein excretion were measured every 2 weeks. At the end of the study, serum creatinine was determined, and renal tissues were obtained for light microscopic examination. SBP was markedly reduced by 8-week antihypertensive treatment. (control, 267±7 mmHg; efonidipine, 181±7 mmHg; enalapril, 200±12 mmHg; nifedipine, 184±6 mmHg). Glomerular sclerosis developed markedly in the control group, but was partially prevented in all treated groups. Similarly, urinary protein excretion (UPE) was suppressed by efonidipine (180±16 mg/day) and enalapril (186±16 mg/day vs. 301±28 mg/day for control). In contrast, nifedipine failed to prevent the increase in urinary protein excretion (258±22 mg/day). In conclusion, efonidipine attenuates SBP increase and ameliorates glomerular injury as well as nifedipine and enalapril. Furthermore, beneficial effects of efonidipine, but not nifedipine, on proteinuria suggest that different mechanisms mediate the improvement of proteinuria; one possible mechanism could be efferent arteriolar dilation, not reported in nifedipine.

KW - Calcium antagonists

KW - Efonidipine

KW - Enalapril

KW - Glomerular injury

KW - Hypertension

KW - Nifedipine

UR - http://www.scopus.com/inward/record.url?scp=0031922876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031922876&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 295

EP - 312

JO - Clinical and Experimental Hypertension

JF - Clinical and Experimental Hypertension

SN - 1064-1963

IS - 3

ER -